Choreo LLC Raises Stock Holdings in DaVita Inc. (NYSE:DVA)

Choreo LLC raised its position in shares of DaVita Inc. (NYSE:DVA) by 20.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,706 shares of the company’s stock after buying an additional 285 shares during the quarter. Choreo LLC’s holdings in DaVita were worth $256,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. FMR LLC grew its holdings in DaVita by 659.9% in the third quarter. FMR LLC now owns 177,406 shares of the company’s stock worth $29,082,000 after purchasing an additional 154,061 shares during the period. Glenmede Trust Co. NA boosted its position in shares of DaVita by 731.6% in the 3rd quarter. Glenmede Trust Co. NA now owns 123,269 shares of the company’s stock worth $20,207,000 after purchasing an additional 108,446 shares in the last quarter. JPMorgan Chase & Co. increased its position in DaVita by 17.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock valued at $99,846,000 after buying an additional 92,014 shares in the last quarter. KBC Group NV raised its stake in DaVita by 27.3% during the third quarter. KBC Group NV now owns 313,519 shares of the company’s stock valued at $51,395,000 after buying an additional 67,250 shares during the last quarter. Finally, International Assets Investment Management LLC bought a new stake in DaVita in the third quarter worth $10,346,000. Institutional investors own 90.12% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Barclays upped their price target on shares of DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, DaVita has a consensus rating of “Hold” and an average target price of $161.80.

DaVita Trading Down 11.4 %

Shares of DVA stock opened at $156.95 on Friday. The stock’s 50-day moving average price is $161.41 and its 200-day moving average price is $157.37. DaVita Inc. has a 12-month low of $118.56 and a 12-month high of $179.60. The stock has a market capitalization of $12.87 billion, a price-to-earnings ratio of 16.93, a price-to-earnings-growth ratio of 0.84 and a beta of 0.94. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Thursday, February 13th. The company reported $2.24 EPS for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. DaVita had a net margin of 6.53% and a return on equity of 88.18%. Equities research analysts predict that DaVita Inc. will post 9.71 EPS for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.